TLR9 and hematopoietic and lymphoid system neoplasm: Pioneering studies by others have demonstrated CpG as an immunostimulatory molecule that activates innate immunity and induces systemic immune response through TLR9 in solid and blood cancer, including B cell lymphoma and melanoma.37